A Revision of Billingham’s Tenets: The Central Role of Lymphocyte Migration in Acute Graft-versus-Host Disease  by Sackstein, Robert
A
R
G
I
t
f
i
t
f
i
t
v
i
ﬂ
p
p
ﬂ
e
t
Biology of Blood and Marrow Transplantation 12:2-8 (2006)
 2006 American Society for Blood and Marrow Transplantation
1083-8791/06/1201-0102$32.00/0
doi:10.1016/j.bbmt.2005.09.015
2Revision of Billingham’s Tenets: The Central
ole of Lymphocyte Migration in Acute
raft-versus-Host Disease
Robert Sackstein
Departments of Dermatology and Medicine, Brigham & Women’s Hospital, Harvard Skin Disease Research
Center, Harvard Medical School, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston,
Massachusetts
Correspondence and reprint requests: Robert Sackstein, MD, PhD, Harvard Institutes of Medicine, 77 Avenue
Louis Pasteur, Suite 671, Boston, MA 02115 (e-mail: rsackstein@rics.bwh.harvard.edu).
Received September 9, 2005; accepted September 28, 2005
ABSTRACT
The migration of cells from vascular to extravascular compartments effects a sequential cascade of events,
involving an interplay between adhesion molecules and chemokines. All T cell–mediated immune responses, of
which acute graft-versus-host disease (GVHD) is an example, require that effector cells reach their target
tissues. Lymphocytes do not enter specific tissues because they “see” a given antigen; they enter because they
possess the requisite combination of homing receptors and chemokine receptors to engage the endothelium at
the target tissue(s). Billingham’s tenets on the immunobiology of GVHD must be expanded to accommodate
this obligatory homing component. Because GVHD is relatively organ specific—principally affecting the skin,
gut, and liver—our increasing knowledge of the pertinent adhesion molecules and chemokines directing
effector cell trafficking to these sites offers novel therapeutic approaches for prevention or treatment of
GVHD. The potential efficiency of this form of therapy could eliminate the use of graft manipulations (eg,
T-cell depletion) and broad immunosuppressives, thereby lessening infectious complications and preserving
the potent graft-versus-malignancy effect of allogeneic hematopoietic stem cell transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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All cells in the blood ﬂow typically exit the vascula-
ure at postcapillary venules, where shear stress ranges
rom 1 to 4 dynes/cm2 [1]. To inﬁltrate tissues, circulat-
ng cells must ﬁrst make adhesive contacts on the endo-
helial wall with sufﬁcient strength to withstand these
orces of blood ﬂow. The molecules that mediate this
nteraction are operationally called homing receptors, and
hey are biophysically specialized to engage their rele-
ant ligands under shear conditions [2]. In analogy, a cell
n blood ﬂow is much like a person swept in a roaring
ood or a river needing ﬁrst to establish a hold on a
assing embankment object. The homing receptors ap-
ly that “braking” grip against the prevailing forces of
ow, without which there would be no opportunity to
scape.
In the early studies of cellular trafﬁcking, it was
hought that tissue-speciﬁc homing would merely tesult from the expression of homing receptors se-
ective for respective ligands expressed on different
issue endothelial beds. However, it was soon clear
hat expression of a homing receptor was necessary
ut not sufﬁcient to achieve tissue-speciﬁc migra-
ion, because various cells could express the same
oming receptor but would show different trafﬁck-
ng patterns. The most striking example of this
aradox was that neutrophils and lymphocytes each
xpress the lymph node homing receptor, L-selectin
CD62L), yet only lymphocytes can migrate into
odes. It was also observed that tissue-speciﬁc hom-
ng receptors could mediate cell migration at sites of
nﬂammation (eg, L-selectin facilitates lymphocyte
nd neutrophil migration in acute and chronic in-
ammatory sites). Moreover, there were increasing
eports that chemoattractants contributed signiﬁ-
antly to homing. Altogether, these observations led
o the notion that “trafﬁc signals” for cellular mi-
g
p
a
l
p
l
t
a
m
ﬂ
c
t
d
i
t
c
c
c
t
t
n
e
t
p
s
t
d
r
p
t
i
a
d
c
m
b
s
h
e
l
t
b
r
a
c
t
H
m
s
m
t
g
m
t
s
t
s
r
o
w
c
m
h
a
ﬁ
e
G
o
l
a
c
t
e
t
i
t
g
r
G
o
a
b
m
c
T
l
r
f
h
l
s
t
s
t
[
m
t
c
T
G
(
(
(
(
Lymphocyte Migration in Acute GVHD
Bration were conferred by the interplay of 2 inde-
endent variables on a given cell—the expression of
relevant homing receptor and the expression of
igand(s) for chemoattractant(s) displayed at the
ertinent site.
The multistep model, which is now well estab-
ished, was then proposed [3,4]. This model holds
hat, initially, cells leave the ﬂuid stream by tethering
nd rolling along the endothelial surface, a process
ediated by the homing receptors (step 1). Cells in
ow are thus exposed to chemical signals (chemokines,
ytokines, and other proinﬂammatory mediators) in
he local milieu (step 2), thereby leading to activation-
ependent upregulation of integrin adhesive capabil-
ties, resulting in ﬁrm arrest (step 3). Firm arrest is
hen followed by transmigration (step 4). Thus, cells
apable of homing to any given tissue must possess the
apacity to crawl along the endothelium with sufﬁ-
ient time to “taste” the local milieu and must possess
he requisite ligands for the environmental chemoattrac-
ants (such as chemokines), thereby triggering adhesive-
ess of surface integrins (such as LFA 1 [L2], to its
ndothelial ligand ICAM-1) directing ﬁrm adherence/
ransmigration. Chemokines are a superfamily of small
roteins that function as potent chemotactic agents,
ome of which have a tissue-speciﬁc and inﬂamma-
ion-speciﬁc distribution, and others that are widely
istributed [5]. Chemokines play multiple roles in the
ecruitment of lymphocytes, promoting not only dia-
edesis but also the localization of lymphocytes within
issue microenvironments. The activation signal for
ntegrin-mediated ﬁrm adherence is typically medi-
ted by G protein–coupled chemokine receptors. The
iscovery that certain homing receptors have limited
ellular distribution and, similarly, that certain che-
okine receptors have restricted, cell-speciﬁc distri-
ution provided a unifying perspective for under-
tanding certain cell migration patterns. For the case of
oming to lymph nodes, it was found that the specialized
ndothelium where lymphocytes egress from the vascu-
ature (the high endothelial venules [HEVs]) constitu-
ively expresses the chemokine SLC (CCL21), which
inds the lymphocyte G protein–coupled chemokine
eceptor known as CCR7. Neutrophils lack CCR7,
nd, therefore, they can roll on HEV but cannot
onvert these interactions into ﬁrm adherence or
ransmigration [6].
OMING AND GRAFT-VERSUS-HOST DISEASE
Acute graft-versus-host disease (GVHD) is a T cell–
ediated inﬂammatory disease. In Billingham’s [7] clas-
ic description of the elements required for the develop-
ent of acute GVHD, 3 requirements were stated: (1)
he host must be incapable of rejecting the graft, (2) the
raft must contain immunocompetent cells, and (3) there l
B&MTust be incompatibilities in transplantation antigens be-
ween donor and host. Although this description is
omewhat challenged by reactions that occur in the set-
ing of blood transfusions and by cyclosporin-induced
yngeneic/autologous GVHD [8], Billingham’s tenets
eﬂect important basic principles in the immunobiology
f GVHD.However, a fourth requirement must be met,
hich was ﬁrst proposed as a corollary to Billingham’s
riteria well over 10 years ago [9,10]: the effector cells
ust migrate to the target tissues (Table 1). This stated
oming requirement has profound clinical implications
nd provides an impetus to modulate lymphocyte traf-
cking as therapy for GVHD.
Several clinical observations highlight the role of
ffector cell migration in the pathobiology of acute
VHD. In the ﬁrst place, the histopathologic diagnosis
f GVHD requires that the involved tissue display a
ymphocytic inﬁltrate [11,12]. Even though essentially
ll tissues express transplantation antigens, the lympho-
yte recruitment is conspicuously skewed geographically
o 3 sites—the skin, gut, and liver. In autoimmune dis-
ases, these organs are also disproportionately affected,
hus suggesting that immune effector cells are “polar-
zed” to trafﬁc to these anatomic sites. Another impor-
ant clinical truth is that the lymphocytic inﬁltrates of
raft-versus-host reactions commonly occur during pe-
iods of profound lymphopenia. Indeed, hyperacute
VHD occurs even before engraftment. Remarkably,
ne often sees pathologic lymphocytic inﬁltrates in the
bsence of circulating lymphocytes, as if the cells are
eing culled from the bloodstream. Thus, the recruit-
ent system that promotes trafﬁcking of alloreactive
ells to the target tissues must be extremely efﬁcient.
he pharmacology of immunosuppressives under-
ies the third main clinical observation: corticoste-
oids, the mainstay therapy of GVHD, have pro-
ound effects on lymphocyte migration patterns. It
as been known for decades that steroids redirect
ymphocyte trafﬁcking away from lymph nodes and
ites of inﬂammation [13], principally by driving
rafﬁcking into bone marrow [14]. This effect of
teroids results in a marked dynamic lymphopenia
hat lasts several hours after drug administration
14]. Notably, calcineurin inhibitors [15,16], rapa-
ycin [17], mycophenolate mofetil [18,19], metho-
rexate [20], and antithymocyte globulins [21,22] all have
onsiderable effects on adhesion molecules that direct
able 1. The Revised Billingham Criteria for the Development of
VHD, with Revision for Homing
1) The host must be incapable of rejecting the graft
2) The graft must contain immunocompetent cells
3) There must be incompatibilities in transplantation antigens
between donor and host
4) The effector cells must migrate to the target tissueseukocyte trafﬁcking; these effects are relatively under-
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4ppreciated and may contribute signiﬁcantly to the ther-
peutic beneﬁt of these agents in GVHD and other
mmune conditions.
All immune processes, from routine immunosurveil-
ance to beneﬁcial host defense to pathologic reactions
uch as GVHD, hinge on one critical fact: lymphocytes
o not enter speciﬁc tissues because they “see” a given
ntigen. They enter because they possess the requisite
ombination of homing receptors and chemokine recep-
ors to engage the endothelium at the target tissue.
hus, for understanding all physiologic and pathologic
ffector cell migration, one needs to know only how a
iven endothelial bed expresses adhesion molecules and
hemokines—either constitutively (homeostatically) or
n response to inﬂammation—and how relevant circulat-
ng effector cells either permanently express or get “im-
rinted” to upregulate the relevant coreceptor molecules
or endothelial adhesion molecules and chemokines.
HE PARADIGMS OF TISSUE-SPECIFIC LYMPHOCYTE
IGRATION: LYMPHOID ORGANS, GASTROINTESTINAL
RACT, AND SKIN
At present, 3 tissue-speciﬁc lymphocyte homing
igure 1. Molecular effectors of naive and effector/memory cell ho
olid black arrows denote cells within efferent lymphatics draini
ymphatics, draining into lymphoid organs; Checkerboard red/whit
enote physiologic lymphocyte recirculation. Boxes and shading/col
hemokines and their respective receptors are paired by italics and c
cid modiﬁcations allow binding to L-selectin (CD62L).eceptors have been identiﬁed: L-selectin for homing po lymph nodes, 47 (LPAM-1) for homing to the
astrointestinal tract and gut-associated lymphoid tis-
ues (GALT), and cutaneous lymphocyte antigen (CLA)
or homing to skin (see review [2]). L-selectin is a mem-
er of the selectin class of adhesion molecules, which
ncludes 2 other members: E- and P-selectin (CD62E
nd CD62P, respectively). As the name implies, all
electins are lectins that bind carbohydrate determi-
ants expressed on their respective ligands. L-selectin
s expressed on leukocytes and is routinely expressed at
igh levels among lymphocytes that migrate continu-
usly to lymph nodes, such as naive lymphocytes and
entral memory lymphocytes; these cells move fre-
uently between lymph and blood, exiting nodes via
fferent lymphatics and gaining reentry to the circu-
ation (via the thoracic duct, typically), where they
hen home to another lymph node (Figure 1). This
ycle is called physiologic lymphocyte recirculation and is
n important process for immunosurveillance [23].
owever, L-selectin expression is characteristically
ow on effector and effector memory lymphocytes;
lternatively, these cells bear high-level expression of
issue-speciﬁc homing receptors, such as those that
irect trafﬁcking to gut and skin. In addition to the
lymph node, skin, and gut. Arrows show the direction of homing:
thoracic duct; Hashed blue arrows denote cells within afferent
s denote cells within the vascular compartment. Enlarged arrows
tify relevant receptor/ligand pairs for adhesion molecules. Pertinent
sterisk on MAdCAM denotes that, when present, specialized sialicming to
ng into
e arrow
or iden
olor. Aermanent expression of the chemokine CCL21 noted
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Lymphocyte Migration in Acute GVHD
Breviously, selectivity in L-selectin–mediated homing
o lymph nodes is due to constitutive expression of
-selectin ligands on HEV, known collectively as pe-
ipheral lymph node addressins. Although the expres-
ion of peripheral lymph node addressins may be in-
uced at certain inﬂammatory sites, their permanent
xpression (and that of CCL21) on HEV ensures that
-selectin/CCR7 lymphocytes home to lymph
odes.
Antigen-driven lymphocyte differentiation occurs
referentially within lymph nodes, because these tis-
ues are architecturally specialized to promote antigen
resentation, cell-cell interactions, and cytokine-medi-
ted communication among immune precursor cells.
he generation or suppression of the immune response,
herefore, is intimately related to the trafﬁcking of anti-
en-presenting cells and of facilitating or regulatory
ymphocytes, respectively, to the lymph nodes [9]. Ac-
ordingly, there is a selective advantage in recruitment
f regulatory cells to the lymph nodes in dampening
lloreactivity. One current strategy to suppress GVHD
s aimed at augmenting the expression of L-selectin or
nriching for the expression of L-selectin among regu-
atory cells in an effort to promote the migration of these
ells to lymph nodes [24,25]. However, successful anti-
en presentation to a naive T cell (such as by dendritic
ells) triggers the transition to an effector/memory
ymphocyte. These lymphocytes then exit the lymph
ode via efferent lymphatics, ﬂowing therein to the
horacic duct and ultimately entering the blood-
tream, where they then preferentially migrate to their
arget tissue. Thus, other strategies for preventing/
reating GVHD are currently aimed at blunting the
odal egress of “educated” alloreactive lymphocytes
as well as naive and central memory cells), such as by
se of the immunosuppressive FTY720 [26,27].
The homing of lymphocytes to GALT and to
ntestinal lamina propria is mediated principally by the
ntegrin 47 [28]. This molecule is expressed at high
evels on gut-homing effector and memory lympho-
ytes and binds a ligand known as mucosal addressin
ell adhesion molecule 1, which is permanently ex-
ressed on HEV of GALT (including mesenteric
ymph nodes and Peyer patches) and the microvascu-
ar endothelium of the intestinal lamina propria. No-
ably, L-selectin can also bind mucosal addressin cell
dhesionmolecule 1 onHEV that bears specialized sialic
cid modiﬁcations [29] and can therefore also contribute
o lymphocyte migration to GALT. In turn, lympho-
ytes homing to the small intestine bear chemokine re-
eptors for a chemokine, TECK (CCL25), that is con-
titutively expressed (and increased by inﬂammation)
ithin the crypts and lower villi of the small intestinal
pithelium and on small intestine lamina propria en-
othelium [5]. Although the expression of 47 is oblig-
tory for homing throughout the gastrointestinal tract,
he relevant chemokine axis that mediates recruitment to a
B&MThe colon is unknown; it is distinct from TECK/CCR9,
ecause only a small fraction of colonic lymphocytes
xpress CCR9 and because TECK is absent from colon
ndothelium [5].
Migration of lymphocytes to skin is directed by
LA, a specialized glycoform of P-selectin glycopro-
ein ligand (PSGL)–1 (see review [30]). PSGL-1 is a
ell-surface mucin-like glycoprotein that can serve as a
igand for all 3 selectins. In general, E- and P-selectin
re inducible membrane molecules expressed on vas-
ular endothelium (and on platelets, for P-selectin) at
ites of inﬂammation, where they facilitate recruit-
ent of leukocytes via interactions with PSGL-1 on
he leukocyte surface. However, these molecules—
specially E-selectin—are permanently expressed on
ermal microvessels. For ligand activity on PSGL-1
irected to each of the selectins, specialized posttrans-
ational modiﬁcations are required on the core protein
ackbone. In particular, PSGL-1 E-selectin ligand
ctivity depends on critical glycosylations that consist
f sialic acid and fucose modiﬁcations; these glycans
re recognized by the rat immunoglobulin M mono-
lonal antibody HECA452, which is directed against a
ialyl Lewis X–like epitope. Early studies showed that
ost lymphocytes in skin display HECA452 reactiv-
ty, that this CLA determinant was found on a subset
f skin-homing memory T cells, and that the CLA
pitope itself was involved in binding to E-selectin.
ater biochemical studies provided direct evidence
hat only CLA()PSGL-1 functions as an E-selectin
igand [31]. CLA()PSGL-1 expressed on effector/
emory T cells engages E-selectin, which is consti-
utively expressed on human dermal microvasculature,
nd E-selectin expression is further increased by in-
ammation [32]. Notably, high E-selectin levels on
ermal vessels are characteristic of acute cutaneous
VHD [33]. Similar to HEV and to small-intestinal
amina propria endothelial beds, skin vessels also dis-
lay a constitutive chemokine proﬁle consisting of
ARC (CCL17) and C-TACK (CCL27), which are
ecognized by receptors CCR4 and CCR10, respec-
ively, expressed on CLA lymphocytes ( see review
30]). Inﬂammation strongly upregulates the expres-
ion of these molecules together with E-selectin, thus
ncreasing, in parallel, the degree of T-cell inﬁltration.
IMPRINTING” OF HOMING CAPABILITIES AND
ELECTIVE MODULATION OF HOMING PATTERNS
The anatomic lymph node in which a naive lym-
hocyte is “educated” inﬂuences the proﬁle of the
dhesion molecule(s) and chemokine receptor(s) ex-
ressed by the effector or memory cell. For example,
ffector lymphocytes exiting via efferent lymphatics of
kin-draining lymph nodes express high levels of CLA
nd negligible levels of 47, whereas the opposite is
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6rue of lymphocytes emerging from mesenteric lymph
odes. This reciprocal polarization extends to the
ypes of chemokine receptors these cells express, fa-
oring their extravasation into skin or gut tissues,
espectively (Figure 1). It is known that dendritic cells
hat reside within these alimentary or peripheral (cu-
aneous) nodal tissues induce the homing phenotypes
n the respective resident lymphocytes. Until re-
ently, however, the molecular basis of this inﬂuence
n the expression of relevant homing and chemokine
eceptors was unknown. A series of elegant studies by
wata et al. [34] showed that retinoic acid enhances the
xpression of 47 and of CCR9 concurrently on T
ells upon activation, whereas it suppresses the expres-
ion of CLA and CCR4. It is important to note that
endritic cells isolated from GALT—but not from
eripheral lymph nodes—speciﬁcally possess enzymes
apable of metabolizing retinol (vitamin A) to retinoic
cid. These ﬁndings provide direct evidence for a role
f retinoic acid in biasing lymphocyte homing to the
ut. The current model suggests that acquisition of
he skin-homing phenotype may reﬂect a default path-
ay, but it certainly does not exclude the possibility
hat a distinct biochemical process may directly induce
he acquisition of skin-seeking molecules. In fact, the
ontrol of CLA synthesis is intimately tied to expres-
ion of speciﬁc glycosyltransferases that are induced
y certain interleukins (eg, induction by interleukin-2
nd -12 and inhibition by interleukin-4; see reviews
2,30]). In any case, these recent ﬁndings open the
xciting possibility that modulating the metabolism of
itamin A or the activity of the relevant receptors on
ymphocytes (retinoic acid receptor  or ) may allow
or selective interference with the elaboration of gut-
r skin-homing phenotypes. It is possible that this
odulation could result in the redirection of effector
rafﬁcking, thus resulting in worsening GVHD at the
eciprocal site (eg, blunting retinoic acid could accen-
uate cutaneous GVHD. If so, modifying retinoic
cid biology, combined with selective interference
ith other components of the homing cascade, could
esult in a favorable therapeutic approach. For exam-
le, we have exploited the requirement for de novo
lycan synthesis in the elaboration of the CLA epitope to
lock dermatotropism of lymphocytes. By using a novel
uorinated analogue of N-acetylglucosamine (2-acet-
mido-1,3,6-tri-O-acetyl-4-deoxy-4-ﬂuoro-d-glucopyr-
nose, otherwise known as 4-F-GlcNAc) that prevents
he synthesis of the polylactosamine carbohydrate chain
resenting the CLA epitope on PSGL-1, both in vitro
35] and in vivo [36] experiments have shown a dramatic
ecrease in CLA synthesis and in lymphocyte homing
o skin in a model of contact hypersensitivity. Nota-
ly, administration of this agent in vivo prevented
nly effector cell migration to skin without compro-
ising the sensitization phase, thus achieving a pro-ound anti-inﬂammatory effect without blunting im- oune responses critical to host defense. Another
romising approach is to interfere with homing by use
f antibodies to disrupt engagement either of homing
eceptors or of relevant chemokines. This approach
as shown some promise in dampening homing to gut
n preclinical studies of acute GVHD [37,38]. Again,
o attain maximal beneﬁts, this strategy could be com-
ined with metabolic inhibition of CLA synthesis
nd/or with agents that target the retinoic acid axis.
YMPHOCYTE MIGRATION AND HEPATIC GVHD:
MOVING TARGET
In contrast to that of the gut and skin, our knowl-
dge of the molecular effectors of lymphocyte migra-
ion to the liver in acute GVHD is relatively incom-
lete. There is circumstantial evidence that links the
ntegrins 47 and 41 (VLA-4) in this process
39,40]. Recently, intravital microscopy studies in a
odel of murine liver inﬂammation (not GVHD)
ave indicated that T-helper type 1 cells may use
LA-4 to trafﬁc to liver, whereas T-helper type 2 cells
ay use a presently uncharacterized ligand for VAP-1,
n endothelial molecule that is constitutively ex-
ressed on hepatic venules and sinusoids and is up-
egulated by liver inﬂammation [41]. There are also data
hat link the hyaluronan receptor CD44 in lymphocyte
oming to liver [42]. This may be relevant to liver
VHD because we have identiﬁed this molecule as a
ediator of shear-resistant binding of human lympho-
ytes to human dermal endothelium in acute cutaneous
VHD [43]. Among chemokines, the CCR5 axis has
ttracted attention in murine studies as a potential me-
iator of recruitment of T cells in liver GVHD, but this
onnection seems to be biased by host conditioning: in
articular, studies in parent-to-F(1) transplantation
odels have linked donor lymphocyte CCR5 expres-
ion with bile duct and sinusoid expression of CCR5
igands (especially CCL3 [macrophage inﬂammatory
rotein 1]) in the pathogenesis of hepatic GVHD
44,45], yet, most relevant to clinical practice, the
dministration of donor CCR5/ lymphocytes in
rradiated recipients actually increased T-cell inﬁl-
rates in liver [46]. Certainly, further studies of rele-
ant adhesion molecules and chemokines are required
efore we can establish clinical strategies to selectively
arget hepatotropism in acute GVHD.
UMMARY
The homing requirement to the Billingham crite-
ia of graft-versus-host reactions is supported by ex-
ensive clinical observations on the pathobiology of
VHD and by our increasing understanding of the
mmunobiology of lymphocyte homing. The inverse
f the homing requirement—ie, GVHD cannot occur
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Lymphocyte Migration in Acute GVHD
Bnless effectors migrate to the target tissues—predicts
hat GVHD can be prevented or treated effectively by
pplying our evolving knowledge of the molecular
asis of lymphocyte trafﬁcking. Our challenge is to
etermine whether preventing lymphocyte migration
o one site will result in redirected pathobiologic tro-
ism to another site, thus, in effect, swapping GVHD
rom one anatomic compartment to another. Still, our
resent knowledge supports the notion that, at least
or graft-versus-host reactions that involve the gut and
kin, the promise of therapeutic approaches that target
oming is within reach. Although outside the scope of
his review, another challenge is to devise strategies to
romote migration of pertinent native effectors or
rogram, ex vivo, the trafﬁcking patterns of expanded
ffectors to relevant tissues in the settings of disease
elapse or serious infectious complications (eg, cyto-
egalovirus disease). Clearly, the nature and kinetics
f lymphocyte migration after hematopoietic stem cell
ransplantation are important subjects for intense in-
estigations. Understanding these pathways is of crit-
cal importance to the clinical prevention/manage-
ent of acute GVHD, and they offer the exciting
rospect of eliminating the attendant morbidities
ssociated with broad immunosuppression and maxi-
izing the therapeutic beneﬁts of allogeneic hemato-
oietic stem cell transplantation, such as the graft-
ersus-malignancy effect.
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